Itonic Holdings Ltd. (NASDAQ:ITOC) Sees Significant Decrease in Short Interest

by · The Markets Daily

Itonic Holdings Ltd. (NASDAQ:ITOC – Get Free Report) saw a large decline in short interest in October. As of October 15th, there was short interest totaling 10,047 shares, a decline of 95.1% from the September 30th total of 206,400 shares. Based on an average trading volume of 26,939 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the company’s stock are sold short.

Itonic Trading Down 9.6%

Shares of NASDAQ:ITOC traded down $0.27 on Monday, hitting $2.53. 42,679 shares of the company’s stock were exchanged, compared to its average volume of 21,468. The firm’s 50-day moving average is $4.46 and its 200 day moving average is $4.97. Itonic has a 1-year low of $2.33 and a 1-year high of $18.40.

Itonic (NASDAQ:ITOC – Get Free Report) last released its quarterly earnings data on Wednesday, September 30th. The company reported ($0.75) EPS for the quarter. The firm had revenue of $0.05 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Itonic currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on Itonic

About Itonic

(Get Free Report)

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.

Recommended Stories